The aim of this study was to examine the level of compliance and persistence in patients with postmenopausal osteoporosis ( OP ) receiving daily risedronate ( 5 mg ) with either fixed dosing of three different timing regimens ( A : before breakfast ; B : in-between meals ; C : before bedtime ) or with flexible dosing and the effect on urinary N-terminal telopeptide of Type 1 collagen ( NTX-1 ) .